Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05962424 · ClinicalTrials.gov registry record · Phase 1

HNC: Human Neural Circuits Electrophysiology During Cognition

A Phase 1 study of Psychiatric Disorder, sponsored by Stanford University.

Recruiting
Registry status
Phase 1
Development phase
120
Enrollment target
1
Study location

NCT05962424 is a Phase 1 study of Psychiatric Disorder that is actively recruiting participants, run by Stanford University. The registered enrollment target is 120 participants, roughly in line with the 129-participant average among 9 other Psychiatric Disorder trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05962424, a Phase 1 study of Psychiatric Disorder, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
Phase 1
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to understand how ketamine brings about dissociative symptoms.

Conditions Studied

Interventions

  • DRUG Ketamine Hydrochloride

Study Locations (1)

California

  • Stanford University - Palo Alto

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2023-10-05
Est. Completion 2030-09-01
Phase Phase 1

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT05962424

The ClinicalTrials.gov registry entry for NCT05962424 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 129-participant average among 9 other Psychiatric Disorder trials with a reported enrollment target. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Psychiatric Disorder appearing as the primary indexed condition, and to 1 intervention - of which Ketamine Hydrochloride is the first listed.

NCT05962424 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05962424 about?

NCT05962424 is a clinical study titled "HNC: Human Neural Circuits Electrophysiology During Cognition". The purpose of this study is to understand how ketamine brings about dissociative symptoms.

What is the current status of trial NCT05962424?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2023-10-05. Estimated completion is 2030-09-01.

What conditions does trial NCT05962424 study?

This clinical trial studies the following conditions: Psychiatric Disorder.

What interventions are being tested in trial NCT05962424?

The interventions under investigation include: Ketamine Hydrochloride (DRUG).

Who is sponsoring clinical trial NCT05962424?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05962424 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Psychiatric Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.